One Equity Partners (OEP), a mid-market private equity firm, has exited its investment in InfuCare Rx, Inc (InfuCare) through a strategic founder-led equity buyback. Financial terms of the private transaction have not been disclosed.
Founded in 2014, InfuCare has become one of the US’s largest privately held independent providers of specialty infusion therapies at home as well as alternate sites of care. The company focuses on treating rare and chronic conditions such as Myasthenia Gravis, CIDP, Crohn’s, Rheumatoid Arthritis, Primary immunodeficiency disorders and bleeding disorders.
InfuCare operates three segments: Immunoglobulin (IG) Therapy, Specialty Infusion, and Bleeding Disorders, servicing over 14,000 patients across all 50 states with approximately 800 employees.
